Experimental CAR-T therapy targets Hard-to-Treat myeloma
NCT ID NCT07139509
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial is testing a new type of CAR-T cell therapy made from donated umbilical cord blood. The cells are designed to attack two targets (BCMA and CD19) on myeloma cancer cells. Up to 18 adults with relapsed or refractory multiple myeloma will receive the treatment after a short course of chemotherapy. The main goals are to check safety and find the best dose.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
allogeneic cord blood-derived CAR-T cells targeting BCMA and CD19
What this could lead to
If successful, this could lead to a new treatment option for patients with multiple myeloma that has stopped responding to standard therapies.
What could go wrong
This is an early Phase 1 trial with only 18 participants, so safety and side effects are still being evaluated. It may not work for everyone, and there are risks like cytokine release syndrome or graft-versus-host disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY MULTIPLE MYELOMA (MM) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Xi'an No.3 Hospital
RECRUITINGXi’an, Shanxi, 710016, China